Two weeks ago, Eli Lilly's stock dropped 4% on a number: 3,707. That was Foundayo's first full week of prescriptions — roughly 20% of Novo Nordisk's oral Wegovy launch pace. Analysts called it "too early to judge." The market judged anyway. Full-year Foundayo estimates were slashed from $5 billion to $1.3–1.7 billion. The narrative was set: the oral pill was underwhelming.
Then the actual quarter landed. Revenue: $19.8 billion, up 56%. EPS: $8.55, beating consensus by 25%. Guidance raised by $2 billion. The stock gained back everything it lost on Foundayo — and then some, closing up 10%.
The market was watching the wrong drug.
The Drug That Delivered
Foundayo shipped April 6. The quarter ended March 31. Zero Foundayo revenue in Q1. Everything that beat — and it beat by a lot — came from the existing tirzepatide franchise.
| Drug | Q1 Revenue | Estimate | Beat | YoY Growth |
|---|---|---|---|---|
| Mounjaro (worldwide) | $8.66B | $7.26B | +$1.40B | +125% |
| Zepbound (US) | $4.10B | $4.04B | +$0.06B | +79% |
| Combined tirzepatide | $12.80B | — | — | +110% |
Mounjaro alone beat estimates by $1.4 billion. In a single quarter. That $1.4 billion overshoot is roughly what analysts expect Foundayo to generate in its entire first year.
The international story is particularly striking. Mounjaro revenue outside the US hit $4.4 billion — up from $1.2 billion a year ago. Volume surged 95% internationally. The China NRDL inclusion crushed realized prices by 25%, but the volume overwhelmed it by a factor of four.
The Guidance Raise
Full-year 2026 guidance, raised across the board:
The midpoint of the new revenue range implies 28% growth over 2025. For a company generating $80+ billion in annual revenue, that growth rate is extraordinary. Lilly is growing like a mid-cap biotech at mega-cap scale.
The Buried Signal: Volume Ate the Price Cut
Here's what the +10% stock move didn't price in: the pricing erosion is real and accelerating.
US realized prices declined 7% in Q1 — or 10% excluding a one-time rebate adjustment that flatters the headline. International prices collapsed 25%, driven by China's National Reimbursement Drug List forcing Mounjaro pricing concessions. Gross margin as a percentage of revenue fell 0.9 percentage points to 82.6%.
Management guided for "low to mid-teens" price headwinds for the full year. And the pricing pressure is about to intensify on three fronts:
Right now, volume is winning. US volume grew 49%. International volume grew 95%. The math works: prices fell 10%, volume rose 49%, revenue surged 43% in the US. But the one-time rebate adjustment that made US price look like -7% instead of -10% won't recur. And each new access channel — Medicare, LillyDirect, China — adds volume at progressively lower realized prices.
Foundayo: The Appetizer
CEO Dave Ricks was measured on the call. In-person HCP promotion didn't start until April 17 — eleven days after launch. Full-scale consumer TV advertising doesn't begin until Q3. The company is treating Foundayo as a slow build, not a launch-quarter revenue driver.
That's the right framing, and the market's pre-earnings panic now looks premature. Judging Foundayo's first-week scripts against Novo's oral Wegovy ignores that Lilly is launching with obesity as the first indication — not diabetes — and hasn't even turned on the demand engine yet. The real test is Q3–Q4, when DTC advertising drives awareness and Medicare coverage unlocks the 65+ population.
Foundayo's long-term potential is real. Oral GLP-1 at $149/month self-pay, $25/month insured, is a different addressable market than injectable tirzepatide. Ricks estimated global GLP-1 patients will grow from 20 million to 30 million by year-end 2026. Foundayo exists to capture the incremental 10 million who won't inject.
But the Q1 story isn't Foundayo. It's Mounjaro at $8.66 billion.
The Verdict
The market's +10% is correct. The core tirzepatide franchise is accelerating faster than any analyst modeled — Mounjaro's $1.4 billion estimate beat alone exceeds Foundayo's full-year revenue expectations. The guidance raise to $82–85 billion confirms management confidence. Lilly holds 60.1% of the US GLP-1 market and is pulling away from Novo Nordisk, which just reported its first sales decline in 25 years.
But at 40x trailing earnings, the stock needs to prove something the Q1 numbers can't: that volume can keep outrunning price. Every new access channel — Medicare at $50/month, LillyDirect at $299/month, China NRDL at -25% — adds patients at lower margins. The gross-to-net erosion is accelerating. The one-time rebate adjustment that made Q1 pricing look better than reality won't repeat.
The volume runway is there — 20 million patients becoming 30 million. But the margin runway is narrowing. The question isn't whether Lilly can grow. It's whether it can grow profitably enough to justify the multiple at the prices it's being forced to accept.
The market spent two weeks watching the wrong drug. Now it needs to start watching the right number: revenue per script.